Table II.
Univariate analysis, including immunostaining for GADD45A.
| Parameter | Risk ratio | 95% CI | P-value |
|---|---|---|---|
| Age at surgery, years | 0.805 | ||
| <65 | 1.000 | ||
| >65 | 1.669 | 0.871–3.194 | |
| Gender | 0.866 | ||
| Male | 1.000 | ||
| Female | 0.956 | 0.097-.0435 | |
| Primary tumor | <0.0001 | ||
| T1 | 1.000 | ||
| T2–4 | 8.849 | 4.081–19.230 | |
| Lymph node metastasis | <0.0001 | ||
| N0-3 | 1.000 | ||
| N4 | 3.773 | 2.386–5.952 | |
| Lymphatic invasion | <0.0001 | ||
| Negative | 1.000 | ||
| Positive | 4.975 | 2.283–10.869 | |
| Vein invasion | <0.0001 | ||
| Negative | 1.000 | ||
| Positive | 2.906 | 1.724–4.901 | |
| Immunostaining for GADD45A | 0.013 | ||
| Positive | 1.000 | ||
| Negative | 2.214 | 1.183–4.144 |
CI, confidence interval; GADD45A, growth arrest and DNA damage-inducible 45α; T, tumor; N, node.